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ABSTRACT
Background  Two novel genetic polymorphisms on 
chromosome 6q23 are associated with susceptibility 
to rheumatoid arthritis (RA). Both polymorphisms 
(rs6920220 and rs10499194) reside in a region close 
to the gene encoding tumour necrosis factor α- induced 
protein 3 (TNFAIP3). TNFAIP3 is a negative regulator of 
NF- κ B and is involved in inhibiting TNF-  receptor-  mediated 
signalling effects. Interestingly, the initial associations 
were detected in patients with longstanding RA. 
However, no association was found for rs10499194 in a 
Swedish cohort with early arthritis. This might be caused 
by over-  representation of patients with severe disease in 
cohorts with longstanding RA.
Objective  To analyse the effect of the 6q23 region on 
the rate of joint destruction.
Methods  Five single nucleotide polymorphisms in 
6q23 were genotyped in 324 Dutch patients with early 
RA. Genotypes were correlated with progression of 
radiographic joint damage for a follow-  up time of 5 
years.
Results  Two polymorphisms (rs675520 and rs9376293) 
were associated with severity of radiographic joint 
damage in patients positive for anti-  citrullinated protein/
peptide antibodies (ACPA). Importantly, the effects were 
present after correction for confounding factors such as 
secular trends in treatment.
Conclusions  These data associate the 6q23 region with 
the rate of joint destruction in ACPA+ RA.
INTRODUCTION
Recent whole-  genome association scans have dis-
closed novel genetic polymorphisms associated 
with susceptibility to anti-  citrullinated protein/peptide 
antibody-  positive (ACPA+) rheumatoid arthri-
tis (RA).1 2 Among those, two single nucleotide 
polymorphisms (SNPs), rs6920220 (A allele) and 
rs10499194 (C allele), were found to be indepen-
dently associated with ACPA+ disease. Both SNPs 
map to a single linkage disequilibrium block span-
ning ~60 kb in a region on chromosome 6q23 that 
lacks known genes or transcripts. The closest genes 
are oligodendrocyte lineage transcription factor 3 
(OLIG3) and tumour necrosis factor α-  induced pro-
tein 3 (TNFAIP3). The latter is of potential impor-
tance to RA pathogenesis, as the protein TNFAIP3 
acts as a negative regulator of NF-  κB.3 So far, how-
ever, functional relevance of the reported polymor-
phisms is unknown.
rs6920220 was initially identiﬁ   ed in ACPA+ 
patients with RA (minor allele OR=1.38) origi-
nating from the United Kingdom (UK).1 It was 
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further replicated in an extended UK-  based case–
control study.4 rs10499194 was initially identiﬁ  ed 
in North American ACPA+ patients (the Brigham 
Rheumatoid Arthritis Sequential Study, BRASS; 
minor allele OR=0.67).2 Replication was success-
ful in two additional US cohorts selected from the 
North American Rheumatoid Arthritis Consortium 
(NARAC). Replication failed, however, in ACPA+ 
patients of a Swedish population-  based incep-
tion cohort (the Epidemiological Investigation 
of Rheumatoid Arthritis cohort, EIRA).2 This last 
ﬁ  nding is of interest, as BRASS and NARAC are 
cohorts of patients with longstanding RA (mean 
disease duration BRASS: 15.4±12.8 years5; NARAC: 
14.3±11.1 years6). The EIRA study, however, was 
designed to identify incident cases of RA as soon 
as possible after disease onset, resulting in an esti-
mated mean disease duration at inclusion of only 
10 months.7
Association of a genetic polymorphism in cohorts 
of patients with longstanding disease but absence 
of this association in an early arthritis cohort led us 
to hypothesise that the 6q23 region would be asso-
ciated with disease severity in ACPA+ patients. 
Very little information is currently available on 
the effects of genetic variation on outcome mea-
sures in RA.8 Therefore, we genotyped ﬁ  ve SNPs 
in a Dutch early arthritis cohort (the Leiden Early 
Arthritis Clinic, EAC) and correlated genotyping 
data to progression of radiographic joint damage 
for a maximum follow-  up of 5 years.
PATIENTS AND METHODS
Patients
The Leiden EAC is a population-  based inception 
cohort that includes patients with self-  reported 
symptom duration of ≤2 years.9 DNA samples of 
324 patients consecutively included between 1993 
and 2003 were used for analysis. For further details 
see online supplementary ﬁ  le 1.
SNP selection and genotyping
Five SNPs (rs1878658, rs675520, rs9376293, 
rs10499194 and rs6920220) were selected based 
on a haplotype analysis across the 6q23 locus 
published previously.2 All SNPs are in imperfect 
linkage disequilibrium with one another (supple-
mentary table 1). Genotyping was performed using 
predesigned TaqMan allelic discrimination probes 
(Applied Biosystems, Foster City, California, USA). 
Each 384-  well plate contained 10 ng sample DNA 
per well and at least eight negative and six posi-
tive controls. Genotype calls and clusters were 
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manually checked for discrepancies and doubtful calls were 
rejected. No SNP deviated from Hardy–Weinberg equilibrium. 
Genotyping call rates were 96.5% (rs1878658), 98% (rs675520), 
95% (rs9376293), 94% (rs10499194) and 98.1% (rs6920220).
Serology and radiographs
Serum samples were tested for citrulline-  speciﬁ  c IgG antibodies 
using a commercially available ELISA kit (Immunoscan Mark2; 
Eurodiagnostica, The Netherlands). Radiographs were scored 
according to the Sharp van der Heijde method10 with known 
time order by one blinded, independent trained reader (supple-
mentary ﬁ  le 1).
Statistical analysis
Association between genotypes and radiographic scoring data 
was analysed using SPSS version 16.0 (SPSS, Chicago, Illinois, 
USA). p Values <0.05 were considered signiﬁ  cant. All p values 
reported are two-  sided.
Two approaches were chosen for statistical analysis. First, 
the average increase in Sharp van der Heijde scores during the 
follow-  up period was estimated for each person by regression 
analysis. Subsequently, the average increase (slope) of scores 
for each genotype was compared non-  parametrically using the 
Mann–Whitney rank-  sum test.
We observed an inﬂ  uence of the time of inclusion (1993–2003) 
on the progression of radiographic joint damage, probably 
reﬂ  ecting an improvement of treatment intensity during this 10- 
year time period. To account for this effect, we performed, as a 
second approach, a mixed model analysis described in detail in 
supplementary ﬁ  le 1.
RESULTS
Radiographic scores of 324 Dutch patients with RA (181 
ACPA+, 143 ACPA−) were available for analysis. At least ﬁ  ve 
radiographic follow-  up observations were available in 57% 
of patients. A dominant model was chosen for analysis, as 
the frequency of patients homozygous for the minor allele of 
rs1878658 (G), rs10499194 (T) and rs6920220 (A) was ≤5%. 
Figure 1 depicts the inﬂ   uence of genotypes on radiographic 
joint damage. ACPA+ and ACPA− subgroups were analysed 
separately. Median scores and interquartile ranges (IQR) are 
provided for ACPA+ patients in table 1 (for ACPA− patients, 
see supplementary table 2).
No inﬂ  uence of genotypes on radiographic joint damage was 
seen in ACPA− patients (ﬁ  g 1). In ACPA+ patients, however, 
two polymorphisms showed reproducible association with dis-
ease progression over time. Presence of the G allele of rs675520 
was found to be associated with increased Sharp van der Heijde 
scores, as a signiﬁ  cant difference was observed when the aver-
age increase (slope) in radiographic scores over time was com-
pared with G as the dominant allele (median slope AG/GG=4.6, 
AA=2.3; Mann–Whitney p=0.007). In order to account for an 
effect of improving treatment strategies on radiographic progres-
sion during the 10-  year period in which patients were included 
in the study, we next performed a mixed-  model analysis. This 
analysis identiﬁ  ed the year of inclusion as a signiﬁ  cant variable 
inﬂ  uencing the extent of radiographic joint damage (p=0.005). 
After correcting for the year of inclusion, however, we still 
observed a signiﬁ  cant inﬂ  uence of the G allele of rs675520 (AG/
GG vs AA, p=0.026).
Similar to the G allele of rs675520, we noted an inﬂ  uence of 
the C allele of rs9376293 on progression of radiographic joint 
damage (ﬁ  g 1). The average increase (slope) in Sharp van der 
Heijde scores over time was signiﬁ  cantly higher for C allele carri-
ers than for T homozygotes (median slope CC/CT=4.5, median 
slope TT=3.0, Mann–Whitney p=0.021). After correcting for the 
year of inclusion as described above a trend effect of the C allele 
remained (p=0.097).
For rs1878658, rs10499194 and rs6920220, no signiﬁ  cant inﬂ  u-
ence of individual genotypes on radiographic joint damage was 
noted.
Table 1  Median Sharp van der Heijde scores (M) and interquartile ranges (IQR; 25%–75% centiles) per genotype for patients with ACPA+ RA 
(n = number of patients). Genotypes were combined for rs1878658 (G), rs10499194 (T) and rs6920220 (A), as the frequency of patients homozygous 
for the respective minor allele was ≤5% for these single nucleotide polymorphisms
Year
0 1 2 3 4 5
ACPA+ M IQR n M IQR n M IQR n M IQR n M IQR n M IQR n
rs1878658
  AA 6 2–13 126 14 6–24 111 18 10–32 113 22.5 11–42  98 26.5 14–51.5 86 32 14–51.5  89
 AG/GG 3 1–7   40 12 5.5–20.5  40 17  6–32  39 30 11.5–56.5  34 32 16–69 31 27 17–74  31
rs675520
  AA 9 4.5–13  33 14 6.5–21  32 15  8–27.5  33 19  9–34  27 22 13.5–39.5 24 20 12.5–47.5  21
  AG 5 1–10  83 12 5–21  73 18  9.5–32.5  78 25 11.5–54  68 32.5 14–61 58 33 17–62.5  66
  GG 5 2–11  51 14 7–27  48  18   8–37  43 26 14–48  39 28 16–63 37 32 20–64  35
 AG/GG 5 2–10 134 13 6–24.5 121 18   9.5–33 121 26 12–53 107 32 15–61 95 32 18.5–61 101
rs9376293
  CC 6.5 3–13.5  28 15 9–28  27 27 12–49.5  25 33 15.5–58  24 35 16.5–62 24 35 16.5–56  21
  CT 4 1–9  84 12 5–21  79 17  7–32.5  78 21 10.5–54  66 32 14–68 57 36 20–68  61
  TT 8 3–13  54 14 6–21  46 16 10.5–25.5  50 21 12–30.5  44 23 13.5–38 38 23 13–47  40
  CC/CT 4 2–10 112 13 6–26.5 106 18  8–36 103 28 11–54.5  90 34 15–63 81 36 19–67.5  82
rs10499194
  CC 7 2–12.5  90 14 6–21.5  77 18  9.5–28  82 21 12–35  71 25.5 14–45 62 29 14–48  62
  CT/TT 4 2–7.5  65 12 6–24.5  64 17  7–37  61 31 11–55  55 29.5 14.5–67 50 32 15–68  51
rs6920220
  AA/AG 7 2–12  58 14 6–21  53 20 10–32.5  57 24 12–48  47 32 18–56 35 35.5 18–65  42
 GG 4.5 2–10.5 108 13 6–25  99 16.5  8–30.5  96 22 11–48  86 25 14–61 84 24 14–51  79
ACPA, anti-citrullinated protein/peptide antibodies; RA, rheumatoid arthritis.
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DISCUSSION
The 6q23 region has recently been associated with disease sus-
ceptibility in RA. This region contains no known transcripts. The 
closest genes with known function are OLIG3 and TNFAIP3. 
TNFAIP3 encodes protein A20, a TNFα-  induced negative regu-
lator of NF-  κB.3 11 Decreased levels of A20 lead to uncontrolled 
NF-  κB activity, resulting in increased inﬂ  ammation. This obser-
vation makes TNFAIP3/A20 and the 6q23 region interesting can-
didates which may modulate inﬂ  ammation also in RA.
We were intrigued by recent differential ﬁ  ndings  for 
rs10499194, a SNP on chromosome 6q23 close to TNFAIP3, in 
cohorts with differing disease duration. The major allele (C) was 
found to be associated with disease susceptibility in ACPA+ 
patients with RA in three cohorts with longstanding disease, 
but not in an early arthritis cohort.2 This indicated a potential 
impact of the 6q23 region on disease severity. In order to test 
for such an impact, ﬁ  ve SNPs were genotyped in a cohort of 
Dutch patients with early RA. These SNPs had previously been 
shown to identify common haplotypes in 6q23.2 We identiﬁ  ed 
two SNPs for which the presence of alleles was associated with 
increased joint destruction in ACPA+ patients. Carriers of the 
G allele of rs675520 developed increased Sharp van der Heijde 
scores over time. A similar effect, although weaker, was found 
for the C allele of rs9376293. Interestingly, no association was 
found for any of the SNPs in ACPA− subjects. Although this 
does not exclude the possibility of a contribution of the 6q23 
region to disease severity in ACPA− disease, the latter obser-
vation is in line with recent reports detecting an association of 
the 6q23 region with disease susceptibility in ACPA+ patients 
only.4
No effect on disease severity was observed for rs10499194 
and rs6920220. Based on our data we cannot rule out the pos-
sibility that either SNP exerts a weak effect that requires larger 
sample numbers for detection or that cannot be observed 
during the ﬁ  rst years of disease. Interestingly, we observed 
nominally higher scores for the risk-  conferring A allele of 
rs6920220 without reaching statistical signiﬁ  cance. The dis-
crepancy between SNPs associating with susceptibility and 
radiographic progression also indicates that the causal vari-
ant at this locus has not yet been identiﬁ  ed. Given the large 
area of linkage disequilibrium surrounding these SNPs, further 
ﬁ  ne-  mapping and functional characterisation will have to be 
performed.
Data linking newly identiﬁ  ed genetic polymorphisms to dis-
ease outcome in RA are only beginning to emerge. Our data are 
unique, as they cover a long period of radiographic follow-  up 
and have been scrutinised for artefacts such as secular trends 
in treatment intensity. Albeit based on relatively small patient 
numbers, our data indicate a contribution of the 6q23 region 
to the rate of joint destruction in ACPA+ RA, thereby fur-
ther reﬁ  ning our understanding of the effects exerted by this 
locus. Replication of our ﬁ  ndings in other cohorts is needed. 
Nonetheless, this is the ﬁ  rst study demonstrating such an effect 
for genetic polymorphisms located outside the HLA-  region in 
ACPA+ patients with RA.
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